CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jakowlew, S. B.
Right arrow Articles by Moody, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jakowlew, S. B.
Right arrow Articles by Moody, T. W.

Cell Growth & Differentiation, Vol 6, Issue 4 465-476, Copyright © 1995 by American Association of Cancer Research


ARTICLES

Expression of transforming growth factor beta ligand and receptor messenger RNAs in lung cancer cell lines

SB Jakowlew, A Mathias, P Chung and TW Moody
National Cancer Institute, Biomarkers and Prevention Research Branch, Rockville, Maryland 20850, USA.

Specific cDNA probes for transforming growth factor beta s (TGF-beta s) 1, 2, and 3 and TGF-beta types I, II, and III receptors were used to study expression of the mRNAs of the different TGF-beta ligand and TGF-beta receptor isoforms in cultured non-small cell lung cancer (NSCLC) cells and small cell lung cancer (SCLC) cells. Expression of TGF-beta 1 mRNA was detected in both cell types using Northern blot hybridization, with the level of expression of this mRNA being higher in several NSCLC cell lines. In addition, expression of TGF-beta 2 and TGF-beta 3 mRNAs was also detected in NSCLC and SCLC cells but at levels that were lower than that of TGF-beta 1 mRNA. Besides expression of a 3.4-kilobase (kb) TGF-beta 3 transcript, a smaller 2.8-kb TGF-beta 3 transcript was detected in some NSCLC and SCLC cells. TGF-beta 1 and TGF-beta 2 proteins were detected in the conditioned media of NSCLC and SCLC cells, with the levels being higher in several NSCLC cells than in SCLC cells. Expression of TGF-beta types I and II receptor mRNAs was also detected in most NSCLC and SCLC cells, with expression of a 5.5-kb type I receptor mRNA being higher than that of a 5.5-kb type II receptor mRNA in both cell types. In contrast, a 6-kb TGF-beta type III receptor mRNA was detected in only some NSCLC cells and could not be detected in the SCLC cells examined. Also, there was an inverse relationship between the level of expression of the 5.5-kb TGF-beta type I receptor mRNA and that of the 6-kb TGF-beta type III receptor mRNA. Addition of TGF-beta 1 and TGF-beta 2 proteins resulted in an increase in the mRNAs for TGF-beta s 1 and 2 and an increase in the amount of TGF-beta 1 protein in some NSCLC cells, indicating that these cells are responsive to TGF-beta and its effects. At the same time, a differential change in expression of the 2.8- and 3.4-kb TGF-beta 3 transcripts was detected in some lung cancer cells following the addition of TGF-beta 1 and TGF-beta 2. Also, addition of TGF-beta 1 to NSCLC cells inhibited colony formation of some of these cells in soft agarose in a dose-dependent manner.(ABSTRACT TRUNCATED AT 400 WORDS)


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
J. Olivares, P. Kumar, Y. Yu, P. B. Maples, N. Senzer, C. Bedell, M. Barve, A. Tong, B. O. Pappen, J. Kuhn, et al.
Phase I Trial of TGF-{beta}2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine
Clin. Cancer Res., January 1, 2011; 17(1): 183 - 192.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Nemunaitis, R. O. Dillman, P. O. Schwarzenberger, N. Senzer, C. Cunningham, J. Cutler, A. Tong, P. Kumar, B. Pappen, C. Hamilton, et al.
Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 10, 2006; 24(29): 4721 - 4730.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. A. Muro-Cacho, M. Anderson, J. Cordero, and T. Munoz-Antonia
Expression of Transforming Growth Factor {beta} Type II Receptors in Head and Neck Squamous Cell Carcinoma
Clin. Cancer Res., June 1, 1999; 5(6): 1243 - 1248.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Ananth, B. Knebelmann, W. Gruning, M. Dhanabal, G. Walz, I. E. Stillman, and V. P. Sukhatme
Transforming Growth Factor {beta}1 Is a Target for the von Hippel-Lindau Tumor Suppressor and a Critical Growth Factor for Clear Cell Renal Carcinoma
Cancer Res., May 1, 1999; 59(9): 2210 - 2216.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
A. Derjuga, C. Richard, M. Crosato, P. S. Wright, L. Chalifour, J. Valdez, A. Barraso, H. A. Crissman, W. Nishioka, E. M. Bradbury, et al.
Expression of p21Waf1/Cip1 and cyclin D1 is increased in butyrate-resistant HeLa cells
J. Biol. Chem., July 26, 2001; (2001) 104735200.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1995 by the American Association of Cancer Research.